I. FREE REGISTRATION IS OPEN! Frontiers in Addiction Research: 2015 Joint NIDA-NIAAA Mini-Convention Friday, October 16, 2015 8am - 5pm, McCormick Place Convention Center, N230, Chicago, IL http://apps1.seiservices.com/nida-niaaa/frontiers2015/Default.aspx
II. FOA: Tools for Monitoring and Manipulating Modified RNAs in the Nervous System
III. Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP1) RFA-DA-16-007 http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-007.html
IV. Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01) PAR-15-120 http://grants.nih.gov/grants/guide/pa-files/PAR-15-120.html#sthash.bBPhto89.dpuf
---------------
I. Frontiers in Addiction Research: 2015 Joint NIDA-NIAAA Mini-Convention Friday, October 16, 2015 8am - 5pm, McCormick Place Convention Center, N230, Chicago, IL http://apps1.seiservices.com/nida-niaaa/frontiers2015/Default.aspx
Registration is open—Please register today to reserve your seat! The National Institute on Drug Abuse [NIDA] and the National Institute on Alcohol Abuse and Alcoholism [NIAAA] are pleased to present the annual Frontiers in Addiction Research [NIDA-NIAAA Mini-Convention] program, a satellite event of the Society for Neuroscience (SfN) Annual Meeting.
For more information about the agenda and registration click http://apps1.seiservices.com/nida-niaaa/frontiers2015/Default.aspx
For additional information on the logistics of the 2015 NIDA-NIAAA Mini-Convention, please contact Caitlin Dudevoir of Synergy Enterprises, Inc. at cdudevoir@seiservices.com.
II. FOA: Tools for Monitoring and Manipulating Modified RNAs in the Nervous System
RFA-DA-16-005, SBIR, R43/R44 mechanism
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-005.html
RFA-DA-16-006, STTR, R41/R42 mechanism,
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-006.html
Purpose: incentivize small businesses to generate tools, technologies, and products for monitoring and manipulating covalently modified eukaryotic RNA, including messenger RNA and regulatory RNA. In the long term, it is hoped that these tools and products will serve as the foundation for future NIDA-relevant research into the molecular mechanisms of substance abuse disorders.
Receipt date: Mid-November, 2015.
Set aside: $2M to fund a total of 5-8 awards for both RFAs.
Budget: Up to $150,000 total costs per year for Phase I and up to $1,000,000 total costs per year for Phase II may be requested.
SBIR or STTR? If the innovative tool to be commercialized will be developed via a partnership of ideas between a small business and an academic/non-profit research institution, consider applying using the STTR mechanism (R41/R42). Small businesses interested in the development of relevant innovative technologies are encouraged to apply via the SBIR mechanism (R43/R44).
Questions: Please contract Kris Bough (boughk@mail.nih.gov) for questions regarding the details of the SBIR/STTR mechanisms. Please contact John Satterlee (satterleej@nida.nih.gov) for scientific questions regarding RNA modifications.
III. Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP1) RFA-DA-16-007
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-007.html
Application Due dates: October 20, 2015 and October 20, 2016, by 5:00 PM local time of applicant organization
Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
The Genetics or Epigenetics of Substance Abuse Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics.
Contact:
Jonathan D. Pollock, Ph.D.
Chief
Genetics and Molecular Neurobiology Research Branch
Division of Basic Neurobiology and Behavioral Research
National Institute on Drug Abuse, NIH
6001 Executive Blvd, Rm. 4257
Bethesda, MD 20892
Tel. 301-435-1309
Email. jpollock@mail.nih.gov
IV. Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01) PAR-15-120 http://grants.nih.gov/grants/guide/pa-files/PAR-15-120.html#sthash.bBPhto89.dpuf
Next application due date: Oct. 20, 2015
The goals of this initiative are to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred non-human animal models using methodologies of Next Gen-Sequencing, mapping, and genotyping. See more information at: http://grants.nih.gov/grants/guide/pa-files/PAR-15-120.html#sthash.bBPhto89.dpuf
Contact:
Jonathan D. Pollock, Ph.D.
Chief
Genetics and Molecular Neurobiology Research Branch
Division of Basic Neurobiology and Behavioral Research
National Institute on Drug Abuse, NIH
6001 Executive Blvd, Rm. 4257
Bethesda, MD 20892
Tel. 301-435-1309
Email. jpollock@mail.nih.gov
--------------
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contactjpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment